ENTA- Clearly, the market has made the ebb and flow connection of Gilead Sciences verses Abbie/ENTA. The Barrons piece may be a drag on ENTA tomorrow.. Not sure it will drop enough to add..
Few years back, analysts predicted that Amylin’s Bydureon for pts with diabetes would bring $3B+ annual sale. Well, these analysts have missed by few miles.
Market Data 
Markets 
AI
